Generation Bio inks $100 mln Series B

Cambridge, Massachusetts-based Generation Bio, a developer of genetic medicines, has secured $100 million in Series B financing. Fidelity Management & Research Company led the round with participation from Invus, Deerfield Management Company, Casdin Capital, Foresite Capital and Leerink Partners’ affiliates.

Source: Press Release